Cg Oncology Inc (CGON)

$25.95 -0.12 (-0.46%)
Market Cap 1.98B
Revenue (ttm) 1.14M
Net Income (ttm) -88.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,722.81%
Debt to Equity Ratio 0.00
Volume 1,279,800
Avg Vol 1,350,676
Day's Range N/A - N/A
Shares Out 76.23M
Stochastic %K 48%
Beta 0.86
Analysts Strong Sell
Price Target $60.33

Company Profile

CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC p...

Industry: Biotechnology
Sector: Healthcare
Phone: 949 409 3700
Address:
400 Spectrum Center Drive, Suite 2040, Irvine, United States
monterocky848
monterocky848 Jun. 27 at 5:52 PM
$CGON shocking another week of jack shit except fade
0 · Reply
BigBill187
BigBill187 Jun. 25 at 1:34 AM
$CGON how long after phase 3 ends is typical approval 6 months plus??
0 · Reply
JayBiotech1
JayBiotech1 Jun. 23 at 1:38 PM
$CGON looks like it may trade back down into low 20's
1 · Reply
swingingtech
swingingtech Jun. 21 at 12:39 AM
$IGT $CGON $GME https://wallstreetwaves.com/significant-friday-options-trading-igt-cgon-gme/
0 · Reply
monterocky848
monterocky848 May. 27 at 5:24 PM
$CGON risk on risk off this stock fucking sucks; Advancing closer n closer sucking more and more
1 · Reply
GoldenCross_92
GoldenCross_92 May. 26 at 2:37 PM
$CGON Rumors of quiet index inclusion are swirling, and big players like Vanguard, Fidelity, and Citadel are piling in - Citadel boosted its stake by over 2,500% in one quarter The stock’s nearly doubled in a year, analysts see $15 ahead, and their CK Gold Project just hit major permitting milestones⁩
0 · Reply
SiRichard83
SiRichard83 May. 26 at 11:31 AM
$CGON 446 watchers
0 · Reply
monterocky848
monterocky848 May. 22 at 5:47 PM
$CGON did u miss the drop from the $30’s to $15 for that great jump
0 · Reply
ZacksResearch
ZacksResearch May. 22 at 5:36 PM
$CGON soared 26.5% this past month — what’s fueling the rally? 🚀 Superior efficacy data from its phase III study of cretostimogene grenadenorepvec for bladder cancer patients hit the market, showing a 75.5% complete response rate at any time point, with 34 confirmed complete response at 24 months, and strong durability. Discover if CGON’s momentum is sustainable 👉 https://www.zacks.com/commentary/2476011/cgon-stock-rallies-27-in-a-month-on-bladder-cancer-study-success?cid=sm-stocktwits-2-2476011-body&ADID=SYND_STOCKTWITS_TWEET_2_2476011_BODY
0 · Reply
monterocky848
monterocky848 May. 21 at 5:11 PM
$CGON up $1.50 now red makes sense as usual
0 · Reply
Latest News on CGON
CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

Jun 23, 2025, 9:58 AM EDT - 5 days ago

CG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 23 days ago

CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 8:00 AM EDT - 6 weeks ago

CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

Apr 28, 2025, 11:14 AM EDT - 2 months ago

CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

Apr 26, 2025, 4:10 PM EDT - 2 months ago

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Apr 2, 2025, 12:32 PM EDT - 3 months ago

CG Oncology Looks Attractive At Current Prices (Rating Upgrade)

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 4 months ago

CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Dec 16, 2024, 4:05 PM EST - 6 months ago

CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

Dec 13, 2024, 2:09 PM EST - 7 months ago

CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene

CG Oncology Announces Pricing of Public Offering

Dec 12, 2024, 8:19 PM EST - 7 months ago

CG Oncology Announces Pricing of Public Offering

CG Oncology Announces Proposed Public Offering

Dec 11, 2024, 6:17 AM EST - 7 months ago

CG Oncology Announces Proposed Public Offering

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

Dec 6, 2024, 1:18 PM EST - 7 months ago

Health Rounds: Experimental CG Oncology immunotherapy shows promise in bladder cancer

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Dec 6, 2024, 8:00 AM EST - 7 months ago

SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Dec 5, 2024, 7:00 AM EST - 7 months ago

Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 30, 2024, 8:00 AM EDT - 10 months ago

CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

CG Oncology: Promising Data, But Looks Expensive

Aug 26, 2024, 10:34 AM EDT - 10 months ago

CG Oncology: Promising Data, But Looks Expensive

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 8, 2024, 8:23 AM EDT - 11 months ago

CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

Jul 9, 2024, 9:19 AM EDT - 1 year ago

CG Oncology Bringing Undervalued Innovation To Bladder Cancer

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

Jun 6, 2024, 12:14 PM EDT - 1 year ago

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

May 24, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

May 9, 2024, 8:00 AM EDT - 1 year ago

CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

May 6, 2024, 1:04 PM EDT - 1 year ago

CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 3, 2024, 11:23 AM EDT - 1 year ago

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

Apr 26, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

Apr 24, 2024, 10:00 AM EDT - 1 year ago

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Mar 28, 2024, 8:00 AM EDT - 1 year ago

CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22, 2024, 8:55 AM EST - 1 year ago

Protara: A Bombed Out Biotech With A Very Positive Skew

TARA

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 30, 2024, 7:00 AM EST - 1 year ago

CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

Jan 29, 2024, 8:14 AM EST - 1 year ago

American Healthcare REIT, Fortegra and Fractyle Health set IPO price ranges as thaw continues

BTSG

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Jan 27, 2024, 1:30 AM EST - 1 year ago

U.S. IPO Weekly Recap: Biotech CG Oncology Pops 96% In A 7 IPO Week

Biotech's First IPO of 2024 Popped 96%. What It Means.

Jan 26, 2024, 11:50 AM EST - 1 year ago

Biotech's First IPO of 2024 Popped 96%. What It Means.

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

Jan 25, 2024, 2:20 PM EST - 1 year ago

CG Oncology's Lead Bladder Cancer Drug Offers A Strong Potential Revenue Stream With Buyout Optionality

CG Oncology valued at $1.75 bln in strong market debut

Jan 25, 2024, 1:46 PM EST - 1 year ago

CG Oncology valued at $1.75 bln in strong market debut

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

Jan 25, 2024, 7:51 AM EST - 1 year ago

CG Oncology IPO prices above range and boosts share count in bullish move ahead of trading

CG Oncology Announces Pricing of Upsized Initial Public Offering

Jan 24, 2024, 7:10 PM EST - 1 year ago

CG Oncology Announces Pricing of Upsized Initial Public Offering

monterocky848
monterocky848 Jun. 27 at 5:52 PM
$CGON shocking another week of jack shit except fade
0 · Reply
BigBill187
BigBill187 Jun. 25 at 1:34 AM
$CGON how long after phase 3 ends is typical approval 6 months plus??
0 · Reply
JayBiotech1
JayBiotech1 Jun. 23 at 1:38 PM
$CGON looks like it may trade back down into low 20's
1 · Reply
swingingtech
swingingtech Jun. 21 at 12:39 AM
$IGT $CGON $GME https://wallstreetwaves.com/significant-friday-options-trading-igt-cgon-gme/
0 · Reply
monterocky848
monterocky848 May. 27 at 5:24 PM
$CGON risk on risk off this stock fucking sucks; Advancing closer n closer sucking more and more
1 · Reply
GoldenCross_92
GoldenCross_92 May. 26 at 2:37 PM
$CGON Rumors of quiet index inclusion are swirling, and big players like Vanguard, Fidelity, and Citadel are piling in - Citadel boosted its stake by over 2,500% in one quarter The stock’s nearly doubled in a year, analysts see $15 ahead, and their CK Gold Project just hit major permitting milestones⁩
0 · Reply
SiRichard83
SiRichard83 May. 26 at 11:31 AM
$CGON 446 watchers
0 · Reply
monterocky848
monterocky848 May. 22 at 5:47 PM
$CGON did u miss the drop from the $30’s to $15 for that great jump
0 · Reply
ZacksResearch
ZacksResearch May. 22 at 5:36 PM
$CGON soared 26.5% this past month — what’s fueling the rally? 🚀 Superior efficacy data from its phase III study of cretostimogene grenadenorepvec for bladder cancer patients hit the market, showing a 75.5% complete response rate at any time point, with 34 confirmed complete response at 24 months, and strong durability. Discover if CGON’s momentum is sustainable 👉 https://www.zacks.com/commentary/2476011/cgon-stock-rallies-27-in-a-month-on-bladder-cancer-study-success?cid=sm-stocktwits-2-2476011-body&ADID=SYND_STOCKTWITS_TWEET_2_2476011_BODY
0 · Reply
monterocky848
monterocky848 May. 21 at 5:11 PM
$CGON up $1.50 now red makes sense as usual
0 · Reply
Ms_P
Ms_P May. 21 at 5:00 PM
$CGON UGEN FDA ad comm meeting was negative, should push up CGON?
1 · Reply
monterocky848
monterocky848 May. 19 at 2:01 PM
$CGON fucking tired of this ones movement
0 · Reply
bden21
bden21 May. 14 at 3:30 PM
$CGON piece of trash
1 · Reply
monterocky848
monterocky848 May. 14 at 2:02 PM
$CGON as if the Phase 3 data did not happen
0 · Reply
PubCoInsight_
PubCoInsight_ May. 12 at 1:11 PM
$LUDG’s AI-driven mRNA cancer screening could rival $PFE or $OCEA! Big-league ambitions hint at major volume. 🚀 $CGON traders, read why: https://pubcoinsight.com/ludwig-enterprises-the-otc-biotech-ready-to-break-out-with-game-changing-potential/ #Biotech #LUDG #Investing
0 · Reply
Fib7867
Fib7867 May. 7 at 4:11 AM
#myCGONanalysis $CGON
0 · Reply
Neggudgid
Neggudgid May. 6 at 7:21 PM
$CGON It’s just GON
0 · Reply
CaliPanda
CaliPanda May. 6 at 7:19 PM
$CGON caught the ride right at 22.41, I'm gunna sit it out here.
0 · Reply
Lionhearts_Eng
Lionhearts_Eng May. 6 at 7:13 PM
$CGON I’m out now! I covered at $22.77. She can go up.
0 · Reply
Neggudgid
Neggudgid May. 6 at 7:12 PM
$CGON Hell, I’m not sure 20’s will hold
0 · Reply
Neggudgid
Neggudgid May. 6 at 6:51 PM
$CGON Somebody knows something….
0 · Reply
Neggudgid
Neggudgid May. 6 at 6:51 PM
$CGON Next drop goes to $22
0 · Reply